{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:23:51Z","timestamp":1791239031910,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"15","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Duchenne Muscular Dystrophy"},{"name":"Becker Muscular Dystrophy"},{"name":"Israel Precision Medicine Program","award":["2039\/20"],"award-info":[{"award-number":["2039\/20"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Duchene muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are genetic neuromuscular disorders that affect skeletal and cardiac muscle resulting from mutations in the dystrophin gene (DMD), coding for dystrophin protein. Read-through therapies hold great promise for the treatment of genetic diseases harboring nonsense mutations, such as DMD\/BMD, as they enable a complete translation of the affected mRNA. However, to date, most read-through drugs have not achieved a cure for patients. One possible explanation for the limitation of these therapies for DMD\/BMD is that they rely on the presence of mutant dystrophin mRNAs. However, the mutant mRNAs containing premature termination codons are identified by the cellular surveillance mechanism, the nonsense-mediated mRNA decay (NMD) process, and are degraded. Here, we show that the combination of read-through drugs together with known NMD inhibitors have a synergistic effect on the levels of nonsense-containing mRNAs, among them the mutant dystrophin mRNA. This synergistic effect may enhance read-through therapies\u2019 efficacy and improve the current treatment for patients.<\/jats:p>","DOI":"10.1093\/hmg\/ddad072","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T10:34:31Z","timestamp":1683282871000},"page":"2455-2463","source":"Crossref","is-referenced-by-count":22,"title":["Inhibition of nonsense-mediated mRNA decay may improve stop codon read-through therapy for Duchenne muscular dystrophy"],"prefix":"10.1093","volume":"32","author":[{"given":"Adi","family":"Amar-Schwartz","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology , The Institute for Medical Research Israel-Canada, , Jerusalem 9112001 , Israel"},{"name":"Hebrew University-Hadassah Medical School , The Institute for Medical Research Israel-Canada, , Jerusalem 9112001 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology , The Institute for Medical Research Israel-Canada, , Jerusalem 9112001 , Israel"},{"name":"Hebrew University-Hadassah Medical School , The Institute for Medical Research Israel-Canada, , Jerusalem 9112001 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Elhaj","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology , The Institute for Medical Research Israel-Canada, , Jerusalem 9112001 , Israel"},{"name":"Hebrew University-Hadassah Medical School , The Institute for Medical Research Israel-Canada, , Jerusalem 9112001 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vered","family":"Ben-Hur","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology , The Institute for Medical Research Israel-Canada, , Jerusalem 9112001 , Israel"},{"name":"Hebrew University-Hadassah Medical School , The Institute for Medical Research Israel-Canada, , Jerusalem 9112001 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahava","family":"Siegfried","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology , The Institute for Medical Research Israel-Canada, , Jerusalem 9112001 , Israel"},{"name":"Hebrew University-Hadassah Medical School , The Institute for Medical Research Israel-Canada, , Jerusalem 9112001 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rotem","family":"Karni","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology , The Institute for Medical Research Israel-Canada, , Jerusalem 9112001 , Israel"},{"name":"Hebrew University-Hadassah Medical School , The Institute for Medical Research Israel-Canada, , Jerusalem 9112001 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talya","family":"Dor","sequence":"additional","affiliation":[{"name":"Pediatric Neurology Unit, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem , Jerusalem 9112001 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"issue":"7","key":"2023072112061453400_ref1","first-page":"1","article-title":"Duchenne muscular dystrophy","volume":"71","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2023072112061453400_ref2","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2023072112061453400_ref3","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/sj.embor.7400221","article-title":"Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment","volume":"5","author":"Nowak","year":"2004","journal-title":"EMBO Rep."},{"issue":"7","key":"2023072112061453400_ref4","first-page":"1","article-title":"Duchenne muscular dystrophy","volume":"71","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2023072112061453400_ref5","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/mt.2011.59","article-title":"Current status of pharmaceutical and genetic therapeutic approaches to treat DMD","volume":"19","author":"Pichavant","year":"2011","journal-title":"Mol. Ther."},{"key":"2023072112061453400_ref6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","article-title":"Dystrophin and mutations: one gene, several proteins, multiple phenotypes","volume":"2","author":"Muntoni","year":"2003","journal-title":"Lancet Neurol."},{"issue":"76","key":"2023072112061453400_ref7","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: first global approval","volume":"7617","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"2023072112061453400_ref8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: first approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"2023072112061453400_ref9","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3390\/genes13071241","article-title":"Current outline of exon skipping trials in Duchenne muscular dystrophy","volume":"13","author":"Santorelli","year":"2022","journal-title":"Genes"},{"key":"2023072112061453400_ref10","first-page":"232","article-title":"Antisense oligonucleotide-mediated exon-skipping therapies: precision medicine spreading from Duchenne muscular dystrophy","volume":"4","author":"Matsuo","year":"2021","journal-title":"Japan Med. Assoc. J."},{"key":"2023072112061453400_ref11","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1358\/dot.2019.55.10.3045038","article-title":"Viltolarsen for the treatment of Duchenne muscular dystrophy","volume":"55","author":"Roshmi","year":"2019","journal-title":"Drugs Today"},{"key":"2023072112061453400_ref12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"2023072112061453400_ref13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-0716-2772-3_1","article-title":"Current strategies of muscular dystrophy therapeutics: an overview","volume":"2587","author":"Lim","year":"2023","journal-title":"Methods Mol. Biol."},{"issue":"5","key":"2023072112061453400_ref14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrm1310","article-title":"(2004) nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics","volume":"52","author":"Maquat","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2023072112061453400_ref15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrg2402","article-title":"The multiple lives of NMD factors: balancing roles in gene and genome regulation","volume":"9","author":"Isken","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"2023072112061453400_ref16","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1007\/s00018-021-03809-7","article-title":"Nonsense suppression therapies in human genetic diseases","volume":"78","author":"Martins-Dias","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"2023072112061453400_ref17","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI28523","article-title":"Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin","volume":"117","author":"Linde","year":"2007","journal-title":"J. Clin. Invest."},{"key":"2023072112061453400_ref18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/ijms22010344","article-title":"Synergy between readthrough and nonsense mediated decay inhibition in a murine model of cystic fibrosis nonsense mutations","volume":"22","author":"McHugh","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2023072112061453400_ref19","doi-asserted-by":"crossref","first-page":"15664","DOI":"10.1073\/pnas.1910456117","article-title":"Premature termination codons in the DMD gene cause reduced local mRNA synthesis","volume":"117","author":"Garc\u00eda-Rodr\u00edguez","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"2023072112061453400_ref20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nchembio.304","article-title":"Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin","volume":"63","author":"Schneider-Poetsch","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"2023072112061453400_ref21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/nm.3620","article-title":"Intracellular calcium regulates nonsense-mediated mRNA decay","volume":"20","author":"Nickless","year":"2014","journal-title":"Nat. Med."},{"key":"2023072112061453400_ref22","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.15252\/emmm.201404461","article-title":"5-azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion","volume":"6","author":"Bhuvanagiri","year":"2014","journal-title":"EMBO Mol Med"},{"key":"2023072112061453400_ref23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1750-1172-7-58","article-title":"Rescue of nonsense mutations by amlexanox in human cells","volume":"7","author":"Gonzalez-Hilarion","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"2023072112061453400_ref24","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/nature05676","article-title":"Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements","volume":"446","author":"Lareau","year":"2007","journal-title":"Nature"},{"issue":"17","key":"2023072112061453400_ref25","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nsmb.1750","article-title":"SF2\/ASF autoregulation involves multiple layers of post-transcriptional and translational control","volume":"173","author":"Sun","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2023072112061453400_ref26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jcf.2020.01.007","article-title":"Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren confirmatory trial in cystic fibrosis (ACT CF)","volume":"19","author":"Konstan","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"2023072112061453400_ref27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2217\/cer-2019-0171","article-title":"Safety and effectiveness of ataluren: comparison of results from the STRIDE registry and CINRG DMD natural history study","volume":"9","author":"Mercuri","year":"2020","journal-title":"J. Comp. Eff. Res."},{"key":"2023072112061453400_ref28","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet (London, England)"},{"key":"2023072112061453400_ref29","doi-asserted-by":"crossref","first-page":"12508","DOI":"10.1073\/pnas.1605336113","article-title":"Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression","volume":"113","author":"Roy","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2023072112061453400_ref30","first-page":"43","article-title":"Read-through approach for stop mutations in Duchenne muscular dystrophy. An update","volume":"40","author":"Politano","year":"2021","journal-title":"Acta Myol."},{"key":"2023072112061453400_ref31","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/hmg\/ddx196","article-title":"Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences","volume":"26","author":"Xue","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"2023072112061453400_ref32","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1096\/fj.13-232025","article-title":"DMD transcript imbalance determines dystrophin levels","volume":"27","author":"Spitali","year":"2013","journal-title":"FASEB J."},{"key":"2023072112061453400_ref33","first-page":"430","article-title":"Regulated tissue-specific expression of antagonistic pre-mRNA splicing factors","volume":"4","author":"Hanamura","year":"1998","journal-title":"RNA"},{"key":"2023072112061453400_ref34","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1111\/j.1742-4658.2011.08274.x","article-title":"Shuttling SR proteins: more than splicing factors","volume":"278","author":"Twyffels","year":"2011","journal-title":"FEBS J."},{"key":"2023072112061453400_ref35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.celrep.2012.11.020","article-title":"S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1","volume":"3","author":"Ben-Hur","year":"2013","journal-title":"Cell Reports"},{"key":"2023072112061453400_ref36","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/path.4129","article-title":"The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers","volume":"229","author":"Cohen-Eliav","year":"2013","journal-title":"J. Pathol."},{"key":"2023072112061453400_ref37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nsmb1209","article-title":"The gene encoding the splicing factor SF2\/ASF is a proto-oncogene","volume":"14","author":"Karni","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2023072112061453400_ref38","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1158\/1541-7786.MCR-14-0131","article-title":"Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer","volume":"12","author":"Das","year":"2014","journal-title":"Mol. Cancer Res."}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/hmg\/advance-article-pdf\/doi\/10.1093\/hmg\/ddad072\/50481232\/ddad072.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/hmg\/article-pdf\/32\/15\/2455\/50918981\/ddad072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/hmg\/article-pdf\/32\/15\/2455\/50918981\/ddad072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T08:20:21Z","timestamp":1689927621000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hmg\/article\/32\/15\/2455\/7153053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":38,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,5,5]]},"published-print":{"date-parts":[[2023,7,20]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddad072","relation":{},"ISSN":["0964-6906","1460-2083"],"issn-type":[{"value":"0964-6906","type":"print"},{"value":"1460-2083","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,5,5]]}}}